You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
CSF ferritin predicts CSF Aβ decline in biomarker-determined Alzheimer’s disease
  1. James R Connor
  1. Correspondence to Dr James R Connor, Department of Neurosurgery, Penn State Hershey Medical Center, Hershey, PA 17033, USA; jconnor{at}pennstatehealth.psu.edu

https://doi.org/10.1136/jnnp-2017-317050

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    CSF ferritin relationship to CSF Aβ could be used to identify AD patients for iron chelation therapy

    This JNNP paper by an excellent team of investigators1 has built on many years of study that has shown loss of iron homeostasis in brain of persons with Alzheimer’s disease (AD). As the authors pointed out, iron has been identified with amyloid plaques and has been suggested to promote neurodegenerative processes through inflammation and generation of oxidative stress.2 There is also a considerable literature on  amyloid precursor protein (APP) and iron handling in the brain including the presence of an iron-responsive element on the APP messenger RNA.3 Therefore, iron is clearly implicated in AD pathology and pathogenic processes.

    Using cerebrospinal fluid (CSF) ferritin as a surrogate …

    View Full Text

    Footnotes

    • Contributors JRC is the sole author.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles